NovaBay Pharmaceuticals – Consensus Indicates Potential 328.6% Upside

Broker Ratings

NovaBay Pharmaceuticals with ticker code (NBY) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 3.5 and 1.9 with the average target price sitting at 2.7. Now with the previous closing price of 0.63 this indicates there is a potential upside of 328.6%. The day 50 moving average is 0.62 and the 200 day moving average is 0.73. The company has a market cap of $28m. Find out more information at:

NovaBay Pharmaceuticals, a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and CelleRx Clinical Reset through online sales channels. The company was formerly known as NovaCal Pharmaceuticals and changed its name to NovaBay Pharmaceuticals in February 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is headquartered in Emeryville, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index